|
| Tuesday, October 8, 2024 |
|
|
エーザイ、痛風・高尿酸血症治療剤「URECE(R) Tablets」（一般名：ドチヌラド）についてタイで承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、痛風・高尿酸血症治療剤「URECE(R) Tablets」（一般名：ドチヌラド）について、タイにおいて「痛風、高尿酸血症」の適応で承認を取得したことをお知らせします。 more info >> |
|
|
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia |
| Eisai Co., Ltd. announced today that it has received approval for "URECE Tablets" (dotinurad) in Thailand as a treatment for gout and hyperuricemia. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
エーザイ、サウジアラビアの医薬品販売子会社が事業活動を開始 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、サウジアラビア王国（以下、サウジアラビア）のリヤドに設立した医薬品販売会社「Eisai Pharmaceuticals Single Person Limited Liability Company」（以下、エーザイ・サウジアラビア）が本格稼働し、事業活動を開始したことをお知らせします。 more info >> |
|
|
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia |
| Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Pharmaceuticals Single Person Limited Liability Company (Eisai Saudi Arabia), a pharmaceutical sales subsidiary recently established in Riyadh in the Kingdom of Saudi Arabia (Saudi Arabia). more info >> |
|
| Tuesday, September 24, 2024 |
|
|
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis |
| Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing authorization approval for amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection 25 mg" (mecobalamin) in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. more info >> |
|
|
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements |
| Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements more info >> |
|
| Tuesday, September 17, 2024 |
|
|
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) |
| These late-breaking data were presented for the first time on September 14 (Central European Summer Time) during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2024 (Presentation #LBA3). more info >> |
|
| Thursday, September 5, 2024 |
|
|
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2024, which is taking place virtually and in-person in Barcelona, Spain from September 13 to 17. more info >> |
|
| Monday, September 2, 2024 |
|
|
Eisai Announces Status Relating to Acquisition of Own Shares |
| Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. more info >> |
|
| Thursday, August 22, 2024 |
|
|
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain |
| Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Abeta) monoclonal antibody "Leqembi" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
|
|
|
